ReviewOncology letters2026
Microbiome-based diagnostic biomarkers in pancreatic ductal adenocarcinoma: Current evidence and translational challenges (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, as the majority of patients are diagnosed at an advanced disease stage. CA19-9, the biomarker most commonly used in clinical practice, lacks adequate sensitivity and specificity for early PDAC detection. Increasing evidence indicates that alterations in gut, oral and tumor-associated microbiota are associated with PDAC development and progression, supporting the potential diagnostic value of microbiome-based biomarkers in this disease. Multiple diagnostic models have been developed for PDAC using fecal, salivary or tissue-derived microbial profiles, and the combination of microbial signatures with CA19-9 or metabolomic markers has improved diagnostic performance in a number of cohorts. Despite these advancements, the clinical translation of microbiome-based models remains limited by methodological heterogeneity, patient-related variability, low levels of microbial biomass in pancreatic tissue and a lack of large-scale prospective validation. In addition, the majority of available evidence for microbiota-based alterations in PDAC is derived from retrospective case-control studies, and the reported diagnostic performance should therefore be interpreted cautiously. The present review summarizes current evidence on PDAC-associated microbial alterations and microbiome-based diagnostic models, and discusses the methodological, biological and regulatory challenges that must be addressed before microbiota-based approaches can be integrated into routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.